Advertisement
BLUE 外匯新聞
Bluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates
Bluebird Bio, Inc. (BLUE) reported Tuesday a net loss for the third quarter of $71.73 million or $0.66 per share, narrower than $76.52 million or $0.94 per share in the prior-year quarter.
RTTNews
|
554天前
Bluebird Bio Says FDA Accepts BLA For Lovotibeglogene Autotemcel For Priority Review
bluebird bio, Inc. (BLUE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.
RTTNews
|
693天前
